PHARMACEUTICAL COMPOSITION COMPRISING HUMAN HYALURONIDASE PH20 AND DRUG
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Jan 9, 2025
app pub date -
Oct 28, 2022
filing date -
Oct 28, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed is a pharmaceutical composition containing (a) a drug, (b) a hyaluronidase PH20 or its variant, and (c) a poloxamer-based surfactant. A human PH20 variant contained in the pharmaceutical composition may includes substitution of one or more amino acids at one or more regions selected from an alpha helix 8 sequence (S347 to C381) and a linker (A333 to R346) between alpha helix 7 and alpha helix 8 in a wild-type human PH20 having a sequence of SEQ ID NO: 1 and optionally includes truncation of one or more amino acids at an N-terminus and/or C-terminus in the wild-type human PH20 having a sequence of SEQ ID NO: 1. In addition, the pharmaceutical composition further contains a pharmaceutically acceptable additive, particularly a stabilizer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully